We are pleased to announce that our European subsidiary company, NeoNeuro has recently succeeded with a pre-clinical trial of their blood test for brain amyloid with the collaboration of the Centro Hospitalar de Entre o Douro e Vouga, in Santa Maria da Fiera, Portugal. This… Read More »Successful Pre-clinical Trial of Aptamer-based Blood Test for Alzheimer’s Disease
Welcome to the forefront of scientific exploration, where the power of aptamers is reshaping the boundaries of medicine, diagnostics, and beyond. The aptamer frontier represents a captivating realm of discovery, where researchers and innovators are unlocking previously unimaginable applications and uncharted possibilities. In this blog,… Read More »The Aptamer Frontier: Discovering New Applications and Possibilities
Aptamers, versatile nucleic acid molecules with tremendous potential for targeted therapies and diagnostics, have gained significant attention in recent years. We are among the key players in this exciting field, known for our leadership in aptamer patenting. With employees named on 85 published patent applications… Read More »Innovating the Landscape of Aptamer Intellectual Property: A Look Inside NeoVentures and NeoNeuro
In recent years, the field of therapeutics has witnessed remarkable advancements in the development of novel treatment strategies. Among the emerging approaches, aptamers have emerged as powerful tools with immense potential in various therapeutic applications. Aptamers, short single-stranded nucleic acid or peptide molecules, can specifically… Read More »Unlocking Therapeutic Potential: Aptamers as Promising Tools in Medicine
Aptamer-based biosensors typically consist of three components: the aptamer as the recognition element, a transducer, and a signal output. The aptamer binds to the target molecule, and this binding event is then transduced into a detectable signal by the transducer. The signal output can be… Read More »What Are Aptamer-Based Biosensors & Their Applications?
In the world of molecular recognition and targeted therapies, aptamers have emerged as an alternative to antibodies. These nucleic acid molecules possess a remarkable set of characteristics that make them highly desirable in various fields, including diagnostics, therapeutics, and drug development. Aptamers exhibit exceptional specificity… Read More »Unleashing the Power of Aptamers: A Versatile Alternative to Antibodies
NeoVentures was formed as an aptamer development company in June of 2002, and founded on a very simple principle. Businesses that create real sustainable value for their clients succeed. This does not always seem to be case as we have all seen biotechnology companies that… Read More »Why has NeoVentures succeeded as an Aptamer development company?
We recently asked which of the following applications cannot be done with aptamers? The results were overwhelmingly in favor of one choice: We can go through each option to see how aptamers are indeed able to be used in diagnostics, therapeutics, and drug discovery but… Read More »What Cannot Be Done with Aptamers?
NeoVentures is pleased to announce the successful completion of a project with a Fortune 500 pharmaceutical company resulting in the development of aptamers as tools for high throughput biomanufacturing of drugs. The key advantage of aptamers in this type of application is the capacity to… Read More »Aptamers for Biomanufacturing of Drugs
In our “What is an aptamer” blog, we described that aptamers are synthetically made, single-stranded DNA or RNA molecules. There are inherent differences between DNA and RNA when found naturally. DNA is typically a double-stranded biomolecule composed of A, T, C, and G bases. RNA… Read More »DNA vs RNA Aptamers
English 
French 
Spanish